Jade Biosciences Inc. 是一家總部位於美國的生物技術公司,主要經營業務為開發自體免疫疾病的療法。該公司的總部設在馬薩諸塞州的沃爾瑟姆,目前擁有4名全職員工,並於2021年6月30日首次公開募股(IPO)。Jade Biosciences, Inc. 的主要資產為JADE-001,這是一種實驗性抗增殖誘導配體(APRIL)單克隆抗體,用於治療免疫球蛋白A(IgA)腎病(IgAN)。IgAN是一種自體免疫性疾病,患者的腎臟因含有致病性IgA的免疫複合物而受損,導致蛋白尿和腎功能下降,甚至可能發展為需要透析或移植的末期腎臟病。JADE-001專門設計用於阻斷APRIL蛋白,針對IgAN的根本病因,有潛力降低致病性IgA水平、減少蛋白尿並長期維持腎功能。此外,該公司的研發管線還包括兩個尚未公開的抗體發現項目JADE-002和JADE-003,目前這兩個項目處於臨床前開發階段。
How did JBIO's recent EPS compare to expectations?
The most recent EPS for Jade Biosciences Inc is $, expectations of $-0.64.
How did Jade Biosciences Inc JBIO's revenue perform in the last quarter?
Jade Biosciences Inc revenue for the last quarter is $
What is the revenue estimate for Jade Biosciences Inc?
According to 11 of Wall street analyst, the revenue estimate of Jade Biosciences Inc range from $0.0 to $0.0
What's the earning quality score for Jade Biosciences Inc?
Jade Biosciences Inc has a earning quality score of A-/59.61258. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Jade Biosciences Inc report earnings?
Jade Biosciences Inc next earnings report is expected in 2026-11-09
What are Jade Biosciences Inc's expected earnings?
Jade Biosciences Inc expected earnings is $0.0, according to wall-street analysts.
Did Jade Biosciences Inc beat earnings expectations?
Jade Biosciences Inc recent earnings of $ expectations.